Recorded Presentations from the NCCN 2026 Breast Cancer Congress with Updates from the 2025 San Antonio Breast Cancer Symposium

The NCCN 2026 Breast Cancer Congress with Updates from the 2025 San Antonio Breast Cancer Symposium offers expert insights into current recommendations of care for patients with breast cancer and highlights the latest clinical research updates to assist clinicians in formulating breast c

CDK4/6 Inhibition in Breast Cancer: Expert Perspectives on Integrating Guideline Updates and Recent Advances Into Practice
Experts discuss the latest clinical data and evolving role of CDK4/6 inhibitors in breast cancer across disease stages and explore emerging therapies, biomarker-driven approaches, and considerations for individualizing patient care in this certified on-demand webcast.
Strategies to Reduce Health Disparities and Improve Outcomes in Breast and Prostate Cancer

The goal of this initiative is to increase awareness, knowledge, and competence in the need for culturally sensitive, evidence-based, guideline recommended approaches for the treatment of breast and prostate cancer in Black patients.

NCCN Guidelines® Updates: Breast Cancer - Treatment of Hormone-Sensitive Advanced Breast Cancer

This information was originally presented at the NCCN 23rd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care held in Orlando, Florida, from March 22 - 24, 2018.

NCCN 2026 Breast Cancer Congress with Updates from the 2025 San Antonio Breast Cancer Symposium

The NCCN 2026 Breast Cancer Congress with Updates from the 2025 San Antonio Breast Cancer Symposium offers expert insights into current recommendations of care for patients with breast cancer and highlights the latest clinical research updates to assist clinicians in formulating breast c

NCCN Guidelines® Insights - Breast Cancer, Version 5.2025
The treatment landscape of invasive early-stage and metastatic breast cancer is evolving constantly. These NCCN Guidelines Insights focus on recent updates included in the most recent version (version 5.2025) of the NCCN Guidelines for Breast Cancer specific to workup, locoregional therapy, surveillance, and systemic neoadjuvant/adjuvant therapy recommendations for invasive, nonmetastatic breast cancer.
Archived NCCN Tumor Boards: Optimal Treatment Strategies for Metastatic Breast Cancer
In order to select optimal therapy, the decision-making process for management of metastatic breast cancer should involve careful consideration of the available evidence and available clinical trials and a detailed discussion with patients about the benefits and risks associated with all possible treatment strategies.
NCCN Tumor Boards: Optimal Treatment Strategies for Metastatic Breast Cancer
In order to select optimal therapy, the decision-making process for management of metastatic breast cancer should involve careful consideration of the available evidence and available clinical trials and a detailed discussion with patients about the benefits and risks associated with all possible treatment strategies.
New Tools for Breast Cancer Risk Assessment
It is important for clinicians to learn about these risk assessment models, understand their limitations and benefits, and determine the best breast cancer risk reduction strategy that can be used for an individual.
CDK4/6 Inhibition in Breast Cancer: Expert Perspectives on Integrating Guideline Updates and Recent Advances Into Practice
Join us for this engaging session led by expert oncology faculty to learn the latest evidence and recommendations with CDK4/6 inhibitors for breast cancer. Insights on how to best mitigate CDK4/6 inhibitor–related adverse events will also be highlighted.

Pages

Subscribe to RSS - Breast Cancer